The DENOCHARCOT Trial

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years 10 months later Oct 1, 2025 → Aug 1, 2030
See other at-risk trials from Ole Lander Svendsen

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Oct 1, 2025 to Aug 1, 2030 Show 6 more changesShow less
    • Trial status changed: Unknown → Recruiting
    • Study completion pushed from Oct 1, 2026 to Oct 1, 2030
    • Secondary endpoints: details revised at 3 of 9 entries
    • Study description revised
    • Publications: details revised at 11 of 11 entries
    • Eligibility criteria expanded, about 5 words
  2. Changed Registry marked status Unknown; last known: Recruiting
  3. Site details revised at 2 of 8 sitesv4
  4. Primary completion date: Oct 1, 2023 to Oct 1, 2025v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 8
    • Start date changed from estimate of Sep 1, 2020 to Nov 1, 2020
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ole Lander Svendsen
2 trials monitored
See 1 trial at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia® on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.
Trial Details
NCT Number NCT04547348
Lead Sponsor Ole Lander Svendsen
Conditions
(from sponsor)		 Charcot Foot, Diabetes Mellitus
Related terms Diabetes Mellitus
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov